sign in sign up
<<
Home , Erysipeloid, Scarlet fever, Trench fever

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/042140 A4 28 March 2013 (28.03.2013) P O P C T

(51) International Patent Classification: NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, A61K 31/197 (2006.01) A61K 45/06 (2006.01) RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, A61K 31/60 (2006.01) A61P 31/00 (2006.01) TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, A61K 33/22 (2006.01) ZM, ZW. (21) International Application Number: (84) Designated States (unless otherwise indicated, for every PCT/IN20 12/000634 kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (22) International Filing Date UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 24 September 2012 (24.09.2012) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (25) Filing Language: English EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (26) Publication Language: English TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (30) Priority Data: ML, MR, NE, SN, TD, TG). 2792/DEL/201 1 23 September 201 1 (23.09.201 1) IN Declarations under Rule 4.17 : (72) Inventor; and — of inventorship (Rule 4.17(iv)) (71) Applicant : CHAUDHARY, Manu [IN/IN]; 51-52, In dustrial Area Phase- 1, Panchkula 1341 13 (IN). Published: — with international search report (Art. 21(3)) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, — with amended claims and statement (Art. 19(1)) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (88) Date of publication of the international search report: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 23 May 20 13 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, Date of publication of the amended claims and statement: 25 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, July 2013 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,

< ©

© (54) Title: NON , NON PEPTIDE COMPOUNDS FOR ANTIBIOTIC EFFICACY & SAFETY ENHANCEMENT o (57) Abstract: The present invention provides one or more non antibiotic non peptidic entity to augment antimicrobial activity of one or more antimicrobial agent for combating microbial resistance The non antibiotic non peptidic entity is used individually or in combination with one or more antibiotic as single unit dose or is presented through a suitable medium The non antibiotic non pep - tidic entity make one or more accompanying antibiotic effective by rendering eradication of broadening spectrum and reducing multi bacterial resistance AMENDED CLAIMS received by the International Bureau on 4 June 2013 (04.06.2013)

1. A non-antibiotic, non-peptidic entity to potentiate activity of one or more antibiotic(s) in treatment of (s) caused by one or more microbial resistant strain(s), wherein said entity is selected from the group comprising an effective amount of EDTA disodium, sodium tetraborate, Sodium salicylate, boric acid or a pharmaceutically acceptable salt thereof wherein, said entity is present in range of about 0.15 % to about 15% of said antibiotic.

2. The non-antibiotic, non-peptidic entity of claim 1 , wherein each entity is present in range of about 0.0015 to 1.5%. 3. The non-antibiotic, non-peptidic entity of claim 1 , wherein said microbial resistant strain is selected from the group comprising ESBL, MRSA, VRSA, VISA, VRJE, NDM- 1 , MBL producing strain, aminoglycoside resistance strains, efflux over expressed strains, bio-film producing strains or a combination thereof.

4. The non-antibiotic, non-peptidic entity of claim 1 , wherein said non-antibiotic, non-peptidic entity further comprises citric acid, tannic acid, reserpine, arylpiperazines, alkylaminoquinolones, nocardamines or a pharmaceutically acceptable salt thereof.

5. The entity of claim 1 , wherein said entity is administered either together as a single unit dose with said antibiotic or is administered separately before/after/during administration of said antibiotic.

6. The entity of claim 1 , wherein said entity is delivered in route selected from the group comprising topical, oral, parenteral and ocular route.

7. The entity of claim 1 , wherein said entity is presented in a form selected from the group comprising nano-particles, dry powder, gel, solution or a pharmaceutically acceptable forms thereof. 8. A synergistic antibiotic composition for treatment and containment of bacterial resistance, said composition comprising a non-antibiotic, non-peptidic entity to potentiate activity of one or more antibiotic(s) component in treatment of infection(s) caused by one or more microbial resistant strain(s), wherein said entity is selected from the group comprising an effective amount of EDTA disodium, sodium tetraborate, Sodium salicylate, boric acid or a pharmaceutically acceptable salt thereof; wherein said antibiotic component is selected form the group comprising , , carbapenems, aminoglycosides, sulfonamides, quinolones, , , glycopeptide , oxazolidinones or combinations thereof; and wherein proportion of said non-antibiotic, non-peptidic entity and said antibiotic component is in a range of about 0.15 % to about 15% of said antibiotic. 9. The synergistic composition of claim 4, wherein said non-antibiotic, non-peptidic entity is present either as a single unit dose with said antibiotic component or is present in a suitable solvent medium. 10. The synergistic composition of claim 4, wherein said non-antibiotic, non-peptidic entity further comprising citric acid, tannic acid, reserpine, arylpiperazines, alkylaminoquinolones, nocardamines or a pharmaceutically acceptable salt thereof. 11. The synergistic composition of claim 4, wherein said antibiotic component further comprises one more betalactamase inhibitor selected from the group comprising sulbactam, tazobactarn, Λ clauvulanic acid or a combination thereof. 12. A method of of treating one ore more bacterial infection caused by drug-resistant bacterium, comprising route of administration of selected from the group comprising oral, parenteral (Intravascular IV, Intramuscular IM, Subcutaneous SC), occular, transdermal or combinational administration of an effective amount of a non-antibiotic, non-peptidic entity to a patent under of one or more in pharmaceutically acceptable dosage form of tablet, capsule, syrup, suspension, solution, powder, granules, gel, lotion, ointment, spray and liposomes or a combination thereof. 13. The method of treatment of claim 13, wherein said non-antibiotici non-peptidic entity is present in a proportion of 0.15 % to about 15% of the antibiotic component. 14. The method of treatment of claim 13, drug-resistant bacterium is selected from the group comprising ESBL, MRSA, VRSA, VISA, VRE, NDM- 1 , MBL producing strain, aminoglycoside resistance strains, efflux over expressed strains, bio-film producing strains, influenzae, Neisseria gonorrhoeaea, N. , Staph. Epidermidis, pneumococci, mitis, faecalis, Streptococcus pneumoni; Staphylococcus haemolyticus. 15. The method of treatment of claim 13, wherein said bacteria responsible for the infection bei treated is at least , , Klebsiella pneumonii , , , Proteus mirabil , A. baumannii, Enterobacter spp., Serratia spp, Serratia marcescei Streptococcus species, pneumoniae, Chlamydophila pneumoniae, Legione ,, , Streptococcus viridans, Staphylococc epidermidis, , Morganella morganii, Acinetobacter calcoaceticus, Bacteroic fragilis , species, enterococci, trachomat species, , , bacilliform , monocytogenes, Tropheryma whipplei, staphylococcus a saprophyticus c.braakii and other species thereof showing resistance to one or more antibiotic: 16. The method of treatment of claim 13, wherein said bacterial infection being treated is select from the group consisting of lower respiratory tract infection, skin and skin structure infectk , , Pelvic inflammatory , sepsis, soft tissue infectioi wound ,renal infections, nocardial pulmonary infections, mycobacterial lymphaden , gastrointestinal infections; infections related to abdominal trauma, bloodstrei infections, , plagues; scarlet , , , Haverhill fever, Potom fever, , Carrion's disease, , bacillary epithelioid angiomatos , , , , human monocytotropic , < scratch disease, tularemia, pseudo-infections, legionellosis, noscoccomial infectioi , osteomyehtis, prostatitis, peritonitis, encephalitis, cerebrospinal infectioi infection of cerebrospinal fluid shunt, meningoencephalitis, joint infections, prosthetic jo infections, septic , myonecrosis, echyma gangrenosum, cholecystitis, 'melioidos , epididymitis, bursitis.

17. The method of treatment of claim 13, wherein said bacterial infection comprises infecti condition of one or more of disease condition caused by gram negative and gram positi strains and microbes. 18. Use of an effective amount of one ore more non-antibiotic, non-peptidic entity for preparati of a medicament for the treatment of infection selected from the group comprising Low respiratory tract infection, skin and skin structure infection, urinary tract infection, Gonorrhi Pelvic inflammatory disease, sepsis, soft tissue infections, wound infections, renal infectioi nocardial pulmonary infections, mycobacterial lymphadeniti, leprosy, gastrointestir infections; infections related to abdominal trauma, , anthrax, plagu< scarlet fever, rheumatic fever, cholera, Haverhill fever, Potomac fever, brucellosis, Carrioi disease, trench fever, bacillary epithelioid angiomatosis, leptospirosis, Lyme disea: rickettsiosis, Q fever, human monocytotropic ehrlichiosis, cat scratch disease, tularem pseudo-infections, legionellosis, noscoccomial infections, erysipeloid, osteomyehtis, prostatit peritonitis, encephalitis, cerebrospinal infections, infection of cerebrospinal fluid shu meningoencephalitis, joint infections, prosthetic joint infections, septic arthritis, myonecros echyma gangrenosum, cholecystitis, , mastoiditis, epididymitis, bursitis or combination thereof. 19. The use of claim 19, wherein said non-antibiotic, non-peptidic entity is combined with one more antibiotic component in a proportion of about 0.15 % to about 15% of said antibiotic. STATEMENT UNDER ARTICLE 19 (1)

AMENDMENTS IN THE CLAIMS:

Reason for Amendments: Amendments have been made in view of the observations made by the ISR on the international application of its WO.

Amendment: Presently pending Claims 1 is amended to include limitation of claim 2, claim 2 is removed now and new claim set include claim 1 to 19. Explanation: The embodiments of the present invention disclose non antibiotic, non peptidic compounds for treatment and containment of anti-biotic resistance when used along with antibiotics. It has been found that exposure of bacterial cells to EDTA, sodium borate and sodium salicyllate cause several common mechanism of action that results increased susceptibility of bacterial cell towards antibiotics. The compound is also effective in containment of spread of bacterial resistance as there occurs prevention of transmission of genetic material between microbes through conjugation.

Difference with the cited prior arts are detailed below:

None of the cited prior art can be considered to be relevant for the subject mater of the present invention. Furthermore, none of the prior art can show effective treatment and containment of bacterial resistances for resistance causing microbes such as ESBL, MRSA, VRSA, VISA, VRA, NDM1 and MBL producing strains, aminoglycoside resistance strains, efflux over expressed strains, bio-film producing strains.The compound at a particular amount was surprisingly found to effect eradication of resistance in several ways and same have been conclusively proved at modular level studies. The invention unexpectedly also found to potentiate a wide class of antibiotics an has significant enhancement of prevention of resistance development.

EFFECT OF AMENDEMENT:

In the present invention has multiple benefit in tackling growing microbial resistance as described the compound effectively enhances the potency of several antibiotic drugs.. Such effects have been sign of surprising therapeutic potential of the invention.

In view of the above mentioned amendment made in claims originally filled with the PCT request, it now appears that amended claims now qualify the Patentability.